Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Koninklijke Philips N.V. (NYSE: PHG) is a global leader in health technology focused on improving lives through meaningful innovation. This news hub provides investors and healthcare professionals with centralized access to official press releases and verified updates about Philips' advancements in diagnostic imaging, connected care systems, and personal health solutions.
Discover timely information on product launches, regulatory milestones, and strategic partnerships that shape Philips' position in the healthcare sector. Our curated collection includes earnings reports, technology innovations, and market expansion announcements – all essential for understanding the company's trajectory in medical equipment and digital health solutions.
Key updates cover developments in AI-driven diagnostic tools, telehealth platforms, and sustainable healthcare initiatives. Bookmark this page to stay informed about Philips' progress in addressing critical challenges across radiology, cardiology, and home-based patient care through its integrated health technology ecosystem.
On June 7, 2021, Philips (NYSE: PHG) presented its vision for digital transformation in healthcare at the HIMSS and Health 2.0 European Congress. The company showcased scalable, interoperable informatics solutions designed to enhance clinical decision-making, improve patient outcomes, and reduce care costs. Philips emphasized the rising importance of telehealth, as nearly two-thirds of healthcare leaders prioritize investments in this area. Key themes included Healthcare Anywhere, Digital Transformation, and Precision Care, highlighting Philips' robust solutions aimed at optimizing healthcare delivery.
On June 7, 2021, Philips (NYSE: PHG) and Elekta announced an extended strategic partnership to enhance cancer care through precision oncology solutions. This collaboration aims to improve patient outcomes by offering integrated systems for clearer diagnosis and treatment pathways. Notable benefits include quicker visualization of tumors, optimized treatment strategies, and reduced therapy costs. The partnership focuses on leveraging each company's strengths to enhance interoperability between their systems, ultimately striving for better cancer care delivery.
Royal Philips (NYSE: PHG) announced positive results from the Tack Optimized Balloon Angioplasty (TOBA) II clinical trial, demonstrating that its Tack Endovascular System provides sustained treatment effects over two years for patients with Peripheral Artery Disease (PAD) and Critical Limb Ischemia (CLI). Key outcomes include 73.6% freedom from clinically driven target lesion revascularization and 94.7% target limb salvage in CLI patients. The data, presented at the 2021 New Cardiovascular Horizons conference, highlights the significant clinical benefits and improved quality of life for patients treated with this innovative device.
Philips (NYSE: PHG) and Akumin Inc. announced a strategic collaboration to deploy Philips’ Radiology Operations Command Center across Akumin’s outpatient imaging network. This partnership aims to enhance access, quality, and productivity within Akumin’s operations, which involve over 130 outpatient imaging centers across seven U.S. states. The command center will standardize imaging procedures and improve clinical personnel productivity, addressing key radiology challenges. Both companies emphasize the potential for improved patient outcomes and operational efficiency through this innovative approach.
Royal Philips (NYSE: PHG) is partnering with Viamed, a major Spanish private hospital group, to enhance diagnostic imaging across its facilities. Viamed, with 11 hospitals and 15 healthcare centers in Spain, will implement advanced Philips technology, including MR and CT scanners and a digital radiology room. This collaboration aims to improve patient care and maintain healthcare excellence as emphasized by Viamed's CEO. Philips expresses pride in this partnership, which promises to offer superior health outcomes and experiences for both patients and healthcare professionals.
Royal Philips and the University of California, San Francisco (UCSF) announced a partnership focused on enhancing healthcare delivery through AI and cloud-based interoperability. The collaboration aims to streamline patient experiences, improve access to care, and relieve provider workloads. By utilizing Philips HealthSuite, UCSF will develop personalized solutions that integrate various healthcare systems, ultimately enhancing patient care across their networks. This initiative addresses interoperability challenges and aspires to advance better healthcare outcomes while reducing costs.
Royal Philips (NYSE: PHG) announced a share repurchase plan of up to 2 million shares, totaling approximately EUR 91 million. This initiative aims to fulfill obligations from long-term incentive and employee stock purchase plans. The buybacks will occur through forward transactions in the second quarter of 2021, adhering to the Market Abuse Regulation and the authorization from shareholders on May 6, 2021. Shares are expected to be delivered in 2023.
Royal Philips (NYSE: PHG) announced the launch of its new Spectral Computed Tomography (CT) 7500, enhancing precision diagnostics across various patient demographics, including cardiac, pediatric, and bariatric populations. This intelligent system provides high-quality spectral images at standard dose levels, significantly reducing time to diagnosis by 34%, along with a 25% decrease in repeat scans and a 30% reduction in follow-ups. The CT 7500 aims to mitigate the estimated $12 billion annual costs associated with misdiagnosis and inefficient imaging practices.
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG) has announced the European launch of innovative health technology solutions during the EuroPCR 2021 event (May 18-20). The portfolio includes the Interventional Applications Platform – IntraSight Mobile, facilitating coronary disease therapy, and the OmniWire Pressure Guide Wire, the world’s first solid-core pressure wire for coronary interventions, now CE marked. Additionally, the Philips Laser System simplifies coronary and peripheral atherectomy procedures, enhancing clinical efficiency and patient care.
Royal Philips (NYSE: PHG) announced the integration of its Interventional Hemodynamic System with the Patient Monitor IntelliVue X3 to enhance clinical decision-making and patient monitoring during interventional procedures. This integration allows for continuous monitoring of vital signs and advanced hemodynamic measurements, improving workflow and patient safety. The solution will be showcased at ACC.21 from May 15-17, 2021. While the system is available globally, it is currently not for sale in the U.S.
